Department of Pathology and Laboratory Medicine, Children's Mercy-Kansas City, Kansas City, Missouri; Center for Pediatric Genomic Medicine, Children's Mercy-Kansas City, Kansas City, Missouri.
Center for Pediatric Genomic Medicine, Children's Mercy-Kansas City, Kansas City, Missouri.
J Mol Diagn. 2021 May;23(5):651-657. doi: 10.1016/j.jmoldx.2021.02.003. Epub 2021 Feb 22.
The most recent build of the human reference genome, GRCh38, was released in 2013. However, many laboratories performing next-generation sequencing (NGS) continue to align to GRCh37. Our aim was to assess the number of clinical diagnostic laboratories that have migrated to GRCh38 and discern factors impeding migration for those still using GRCh37. A brief, five-question survey was electronically administered to 71 clinical laboratories offering constitutional NGS-based testing and analyzed categorically. Twenty-eight responses meeting inclusion criteria were collected from 24 academic and four commercial diagnostic laboratories. Most of these (14; 50%) reported volumes of <500 NGS-based tests in 2019. Only two respondents (7%) had already migrated entirely to GRCh38; most laboratories (15; 54%) had no plans to migrate. The two prevailing reasons for not yet migrating were as follows: laboratories did not feel the benefits outweighed the time and monetary costs (14; 50%); and laboratories had insufficient staff to facilitate the migration (12; 43%). These data, although limited, suggest most clinical molecular laboratories are reluctant to migrate to GRCh38, and there appear to be multiple obstacles to overcome before GRCh38 is widely adopted.
人类参考基因组的最新版本 GRCh38 于 2013 年发布。然而,许多进行下一代测序(NGS)的实验室仍在使用 GRCh37 进行比对。我们的目的是评估已经迁移到 GRCh38 的临床诊断实验室的数量,并确定那些仍在使用 GRCh37 的实验室迁移的阻碍因素。我们向 71 家提供基于 NGS 的临床检测的临床实验室发放了一份简短的五问题调查问卷,并进行了分类分析。从 24 家学术实验室和 4 家商业诊断实验室中收集到了 28 份符合纳入标准的回复。这些回复中,大多数(14 份,50%)报告 2019 年的 NGS 检测量<500 次。只有两名受访者(7%)已经完全迁移到 GRCh38;大多数实验室(15 份,54%)没有迁移计划。尚未迁移的两个主要原因如下:实验室认为收益没有超过时间和金钱成本(14 份,50%);以及实验室缺乏足够的人手来协助迁移(12 份,43%)。这些数据虽然有限,但表明大多数临床分子实验室不愿意迁移到 GRCh38,在 GRCh38 得到广泛采用之前,似乎还有多个障碍需要克服。